Showing results (1-10 of 2,352) with videos related to
Sort By:
Pageof 236
Cell Metabolism|November 3, 2021
EMPEROR-Preserved: A promise fulfilledDeepak L Bhatt, Subodh Verma, Bertram PittCardiovascular Drugs and Therapy|November 9, 2021
The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes MellitusBertram Pitt, Gabriel Steg, Lawrence A Leiter, et al.European Heart Journal|January 13, 2009
Patients with peripheral arterial disease in the CHARISMA trialPatrice P Cacoub, Deepak L Bhatt, P Gabriel Steg, et al.The American Journal of Cardiology|May 5, 2007
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry)Benjamin A Steinberg, P Gabriel Steg, Deepak L Bhatt, et al.The Canadian Journal of Cardiology|October 9, 2010
One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registryKim G Smolderen, Alan Bell, Yang Lei, et al.Heart Asia|June 22, 2016
Prevalence and treatment of cardiovascular risk factors in outpatients with atherothrombosis in the Middle EastAlawi A Alsheikh-Ali, Wael A Al-Mahmeed, Avi Porath, et al.European Heart Journal|June 17, 2022
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal diseaseArjun K Pandey, Deepak L Bhatt, Francesco Cosentino, et al.Current Atherosclerosis Reports|July 9, 2008
Medical therapy versus percutaneous coronary interventions for patients with stable and unstable coronary artery diseaseBertram PittHeart Failure Reviews|June 11, 2005
The role of aldosterone blockade in patients with heart failureBertram PittHeart Failure Reviews|October 15, 2011
The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failureBertram PittPageof 236